Residents of Australia’s northern regions have sweltered as a heatwave has continued through the weekend, and is expected to ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated ...

Dr. Randy Schumacher with Topeka’s Stormont Vail Pediatrics says RSV (respiratory syncytial virus) is of particular concern ...

Dr. Kerry-Anne Perkins, a new mom and board-certified OB-GYN shares what parents need to know about RSV and more.

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...